Política de privacidad      Acceso / Registro

sábado, 23 octubre 2021
- Advertisement -


multicriteria decision analysis

Determining the value contribution of emicizumab (hemlibra®) for the prophylaxis of haemophilia a patients without inhibitors in Spain by multi-criteria decision analysis (MCDA)

Marina Tort et. al Determining the value of emicizumab compared to octocog alfa (OA) and efmoroctocog alfa (EA) in the prophylaxis of severe Haemophilia A...

Latest news

- Advertisement -